Skip to main content
FDA orphan status granted to AZ's neurofibromatosis type 1 drug
2/15/2018

AstraZeneca's neurofibromatosis type 1 drug candidate selumetinib received orphan status from the FDA. The company has ongoing Phase I and II trials of the drug in pediatric patients with NF1, with results from the Phase II study anticipated later this year.

Full Story: